---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-008357"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2025-10-23T23:59:59+00:00"
generated_at: "2026-05-17T02:29:57.904421+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ZEO ScientifiX positioned for Florida stem cell market growth after SB 1768 enactment

## Summary
- Florida SB 1768, effective July 1, 2025, allows physicians to administer non-FDA-approved stem cell therapies for orthopedic, wound care, and pain under cGMP.
- ZEO expects revenue growth from increased physician demand, patient awareness, and medical tourism to Florida.
- Company launched IRB-approved clinical study (PPX™) for musculoskeletal joint pathologies, targeting up to 350 patients; 5 clinics enrolled, 7 patients to date.
- ZEO evaluating lab expansion at Nova Southeastern University for additional clean rooms and research space.
- New law enables collection of real-world safety/outcome data, potentially lowering risks for future FDA submissions.

## SEC filing metadata
- accession: 0001829126-25-008357
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2025-10-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912625008357/0001829126-25-008357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912625008357/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-008357
- JSON: https://secwatch.observer/filing/0001829126-25-008357.json
- Plain text: https://secwatch.observer/filing/0001829126-25-008357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.